Rabphilin-3A as a Novel Target to Reverse α-synuclein-induced Synaptic Loss in Parkinson’s Disease

Rabphilin-3A as a Novel Target to Reverse α-synuclein-induced Synaptic Loss in Parkinson’s Disease
Pharmacol Res. 2022 Jul 30:106375. doi: 10.1016/j.phrs.2022.106375. Online ahead of print.ABSTRACTToxic aggregates of α-synuclein (αsyn) are considered key drivers of Parkinson's disease (PD) pathology. In early PD, αsyn induces synaptic dysfunction also modulating the glutamatergic neurotransmission. However, a more detailed understanding of the molecular mechanisms underlying αsyn-triggered synaptic failure is required to design novel therapeutic interventions. Here, we described the ... read more
Source: PubMedPublished on 2022-08-02By Elena Ferrari